Charles River Laboratories Interna revenue and financials

CRL · NYSE · USD

$304.96−1.87%−$5.81

Close · October 6, 2026

In the fiscal year ended December 2025, Charles River Laboratories Interna reported revenue of $4.02B (−0.85% year over year). The net loss was $144.34M.

Annual revenue · 2025: $4.02B
  1. $1.68B2016
  2. $1.86B2017
  3. $2.27B2018
  4. $2.62B2019
  5. $2.92B2020
  6. $3.54B2021
  7. $3.98B2022
  8. $4.13B2023
  9. $4.05B2024
  10. $4.02B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
−0.85%
2025 vs 2024
Net margin
-3.6%
2024: 0.5%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets7,5327,7307,1357,5147,5617,5827,5288,0047,9488,1538,1957,607
Current assets1,5291,4891,4471,5321,4701,5061,4031,4951,4991,6681,6091,444
Cash and equivalents192192214207183229195210179327277157
Receivables712700709734768757721754762787780799
Inventory346360299303280290279336349361380293
Net property, plant and equipment1,8251,8282,0171,9661,9921,9902,0172,0252,0002,0032,0341,901
Goodwill3,0773,0402,7642,9222,9362,8732,8473,1253,0803,0703,0952,885
Other intangible assets253249340571602656723778800828864886
Long-term investments206210207195216214218236233244244302
Current liabilities1,1351,0941,1201,1221,0801,0519941,0129489551,055994
Accounts payable141134149170146149140136133130169136
Long-term debt2,6112,6542,1122,1602,3072,4852,2152,2992,3832,6322,6212,488
Total liabilities4,6444,7423,9244,0634,1614,3414,0204,1764,1754,4494,5364,256
Total equity (incl. minority)2,8892,9883,2113,4513,4003,2423,5083,8283,7733,7043,6593,351
Retained earnings1,3721,3741,3891,9441,8901,8381,8122,1232,0541,9601,8871,720
Minority interest48.947.746.645.446.347.446.645.450.463.562.144.7